Back to news

Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

Globe Newswire•19/11/2026•07:00 ET
0

Key Highlights

  • ➤Adagene (ADAG) doses first patient in Phase 1 ADG138 study
  • ➤Phase 1 will enroll HER2-positive advanced solid tumor patients
  • ➤ADG138 dose escalation starts at 2 mg
  • ➤ADG138 showed approximately 220-fold lower HER2 binding preclinically
  • ➤ADG138 showed greater than 1,000-fold lower CD3 binding preclinically

Expert Statements

Peter Luo, Chairman, CEO and President of R&D at Adagene

“Dosing the first patient with ADG138 is an important step in moving our double-masked T-cell engager from preclinical research into the clinic”

Peter Luo, Chairman, CEO and President of R&D at Adagene

“Our preclinical data showed that masking both the HER2 and CD3 binding sites preserved ADG138’s antitumor activity, including in Enhertu (DS-8201)-resistant models, while reducing cytokine release and widening the therapeutic window compared with an unmasked T-cell engager.”

Peter Luo, Chairman, CEO and President of R&D at Adagene

“Clinical experience with muzastotug, our masked anti-CTLA-4 SAFEbody in IgG1 format, now includes more than 250 patients dosed with high, repeated dosing, and continuous treatment beyond two years in some patients.”

Peter Luo, Chairman, CEO and President of R&D at Adagene

“Together with ADG138’s robust preclinical findings, this reinforces our confidence in extending SAFEbody technology to T-cell engagers.”

Peter Luo, Chairman, CEO and President of R&D at Adagene

“We look forward to evaluating ADG138’s safety and preliminary efficacy in heavily pretreated patients who have progressed after multiple lines of therapies, including standard-of-care and investigational HER2-directed antibody-drug conjugates.”

First-in-human study will enroll patients with HER2-positive advanced solid tumors

ADG138 design includes proprietary IgG1-based heterodimeric format and SAFEbody® double masking to support prolonged circulation and tumor-selective accumulation and activation

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in